| Dr Michael Dean Dail, PHARMD, BCACP | |
|
620 John Paul Jones Cir, Portsmouth, VA 23708-2111 | |
| (757) 953-4524 | |
| Not Available |
| Full Name | Dr Michael Dean Dail |
|---|---|
| Gender | Male |
| Speciality | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist |
| Location | 620 John Paul Jones Cir, Portsmouth, Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043652068 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 0202212257 (Virginia) | Secondary |
| 1835P0018X | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist | 0202212257 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Dean Dail, PHARMD, BCACP 620 John Paul Jones Cir, Portsmouth, VA 23708-2111 Ph: () - | Dr Michael Dean Dail, PHARMD, BCACP 620 John Paul Jones Cir, Portsmouth, VA 23708-2111 Ph: (757) 953-4524 |
News Archive
Tens of millions of people worldwide are affected by diseases like macular degeneration or have had accidents that permanently damage the light-sensitive photoreceptors within their retinas that enable vision.
Two research papers have been released that show that the abstinence-only-until-marriage (AOUM) programs and policies in the United States are ineffective by and large and have not been successful in reducing risky sexual behaviors or early initiation of sex. Studies have reported that these are programs that successfully withhold medically accurate information not to mention infringe on adolescent human rights and reinforce gender stereotypes. The findings are published in the Journal of Adolescent Health.
Two studies are providing new insight into germline epidermal growth factor receptor (EGFR) T790M mutation in familial non-small cell lung cancer (NSCLC). The findings suggest the need for tailored approaches for early detection and treatment, as well as for genetic testing to identify carriers.
Aventis and Sanofi-Synthélabo agreed on a substantially improved offer as well as a balanced governance structure. After reviewing this new offer, the Management Board and the Supervisory Board decided to recommend this offer to Aventis shareholders.
Salix Pharmaceuticals, Ltd. today announced that the Company has submitted an efficacy supplement to NDA 21-361 for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.
› Verified 4 days ago
Dr. Lakeisha Goode, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-7462 | |
Dr. Jesse Michael Daconta, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-5000 | |
Dr. Laura Modafferi, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-7550 | |
Dr. Janelle Fontaine White, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-3989 Fax: 757-953-0865 | |
Mr. Michael Phillip Volstorf, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-0258 | |
Siung Woo Kang, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 559-681-4181 |